CDK4\/6 inhibitors (Pfizer\u2019s palbociclib, Novartis\u2019s ribociclib, and Eli Lilly\u2019s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive \/ HER2-negative disease, and we expect them to drive robust sales in the early-stage setting. Novel biomarker-driven therapies (Novartis’s alpelisib, AstraZeneca\u00b4s capivasertib, and Menarini\u00b4s elacestrant) are effective treatment options, and the market will become increasingly crowded with agents seeking to tackle endocrine resistance. HER2-positive breast cancer treatment is rapidly evolving owing to approval and forecast label expansions for agents such as trastuzumab deruxtecan (Daiichi Sankyo \/ AstraZeneca), which has also emerged as a key therapy for the newly defined HER2-low and HER2-ultra-low subgroups. In triple-negative breast cancer, Merck & Co.\u2019s immune checkpoint inhibitor pembrolizumab is the standard of care, and Gilead\u2019s TROP2-targeted agent sacituzumab govitecan, currently used in the pretreated metastatic setting, aims to expand to more lucrative earlier lines of treatment.<\/p>\n
Questions answered<\/strong><\/p>\n Geography<\/strong>:<\/strong> United States, EU5, Japan<\/p>\n Primary research:<\/strong> Country-specific interviews with thought-leading medical oncologists; survey data collected for this and other Clarivate research<\/p>\n Epidemiology:<\/strong> Diagnosed incidence of breast cancer by country; histology, stage, and line of therapy, segmented into relevant drug-treatable populations<\/p>\n Forecast:<\/strong> 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2034, segmented by brands and epidemiological subpopulations<\/p>\n Drug treatments:<\/strong> Coverage of select current and emerging therapies<\/p>\n Product description<\/strong><\/p>\n Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n